Unicycive Therapeutics Inc
UNCY | $1.155 3.13% 2.61% 140K
|
Professional, Scientific, and T...
(0.0% 1d) (-16.5% 1m) (-31.8% 1y) (0.0% 2d) (3.6% 3d) (-4.9% 7d) (-74.35% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 40,143,684
https://unicycive.com
Sec Filling | Patents | 2021 employees
Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.
treatment kidney
add to watch list Paper trade email alert is off
Press-releases
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
UNCY | $1.155 3.13% 2.61% 140K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.0%
C: -1.52%
conference therapeutics growth
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-28 (Crawled : 20:00) - globenewswire.com
UNCY | $1.155 3.13% 2.61% 140K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
business year update financial results
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
UNCY | $1.155 3.13% 2.61% 140K
|
Professional, Scientific, and T...
|
| O: 1.36%
H: 7.38%
C: 2.01%
congress association renal therapeutics
Unicycive Announces $50 Million Private Placement
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
UNCY | $1.155 3.13% 2.61% 140K
|
Professional, Scientific, and T...
|
| O: 8.63%
H: 14.57%
C: -4.64%
million
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
Published: 2024-03-13 (Crawled : 11:00) - globenewswire.com
UNCY | $1.155 3.13% 2.61% 140K
|
Professional, Scientific, and T...
|
| O: 1.75%
H: 1.03%
C: -4.47%
uni-494 conference presentation therapeutics
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
UNCY | $1.155 3.13% 2.61% 140K
|
Professional, Scientific, and T...
|
| O: -6.67%
H: 10.71%
C: 8.57%
trial therapeutics
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
Published: 2024-03-04 (Crawled : 12:00) - globenewswire.com
UNCY | $1.155 3.13% 2.61% 140K
|
Professional, Scientific, and T...
|
| O: 1.25%
H: 2.46%
C: -8.02%
uni-494 drug kidney granted food designation therapeutics
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
Published: 2024-02-14 (Crawled : 12:00) - globenewswire.com
UNCY | $1.155 3.13% 2.61% 140K
|
Professional, Scientific, and T...
|
| O: 3.81%
H: 7.34%
C: 6.42%
kidney spring meeting therapeutics
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
Published: 2024-01-29 (Crawled : 12:00) - globenewswire.com
UNCY | $1.155 3.13% 2.61% 140K
|
Professional, Scientific, and T...
|
| O: 5.73%
H: 3.24%
C: 1.61%
uni-494 conference presentation therapeutics
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
Published: 2024-01-23 (Crawled : 12:00) - globenewswire.com
UNCY | $1.155 3.13% 2.61% 140K
|
Professional, Scientific, and T...
|
| O: 4.69%
H: 20.69%
C: 12.99%
key therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 42% | 58% |
Top 10 Gainers
UAL | News | $49.705 1.98% 1.7M
|
Transportation
TTEC M | $7.975 1.08% 17
|
Commercial Services
TWO 4 | $11.83 0.42% 13K
|
Finance
TTC 4 | $84.585 0.36% 2.9K
|
Producer Manufacturing
UBER A | $72.19 0.35% 160K
|
Technology Services
UAA | $6.565 0.23% 32K
|
Consumer Non-Durables
TTD 4 | $80.31 0.22% 22K
|
Commercial Services
TWLO | $58.72 -0.03% 24K
|
Technology Services
UBS | $28.08 -0.11% 97K
|
Finance
U | $23.57 -0.63% 130K
|
Technology Services
Last 48 Hours Insiders Buying
IZEA | $2.53 1.2% -2.4% 0
|
Technology Services
|
00:00
RKT P 383 | $11.38 -0.52% 2.64% 5
|
Finance
|
22:30
CTRN P 18090 | $22.37 -1.41% -1.02% 0
|
Retail Trade
|
22:00
BRN P 10650 | $2.79 2.2% 0.0% 0
|
Energy Minerals
|
21:00
NEOG P 10000 | $12.14 -0.16% -0.16% 0
|
Health Technology
|
16:30
RMCF | $3.53 -3.16% -3.85% 0
|
Consumer Non-Durables
|
20:10